DRG Market Assessment reports

Clarivate Epidemiology’s coverage of chronic myeloid leukemia (CML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of chronic myeloid leukemia (CML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of chronic myeloid leukemia (CML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Historically, the prognosis has been poor. Chemotherapy backbones have long dominated treatment, but there is an ongoing…

Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…

Relapsed / refractory (R/R) Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) patients have a poor prognosis. No standard of care has been established for relapsed / refractory…

Clarivate Epidemiology’s coverage of monoclonal gammopathy of undetermined significance (MGUS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key MDS patient populations, covering 171 countries and more than 99% of…

Clarivate Epidemiology’s coverage of myelodysplastic syndromes (MDS) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed…

Clarivate Epidemiology’s coverage of myelodysplastic syndromes (MDS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of acute lymphoblastic leukemia (ALL) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of acute lymphoblastic leukemia (ALL) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…